Brief: Aileron Therapeutics Announces Interim Data From Phase 1B Chemoprotection Trial Of Alrn-6924 In Patients With P53-Mutated Non-Small Cell Lung Cancer (Nsclc) And Confirms Development Path For Alrn-6924 Focused On P53-Mutated Breast Cancer

Rein Therapeutics

29/06/2022 11:46

June 29 (Reuters) - Aileron Therapeutics Inc  ALRN.O :
    * AILERON THERAPEUTICS ANNOUNCES INTERIM DATA FROM PHASE 1B
CHEMOPROTECTION TRIAL OF ALRN-6924 IN PATIENTS WITH P53-MUTATED
NON-SMALL CELL LUNG CANCER (NSCLC) AND CONFIRMS DEVELOPMENT PATH
FOR ALRN-6924 FOCUSED ON P53-MUTATED BREAST CANCER
    * AILERON THERAPEUTICS INC - PLANS TO STOP FURTHER
ENROLLMENT IN
NSCLC TRIAL
    * AILERON THERAPEUTICS - INTERIM FINDING ON TRIAL'S
COMPOSITE
PRIMARY ENDPOINT DEMONSTRATED 56% OF CYCLES ON ALRN-6924 VERSUS
50% OF CYCLES ON PLACEBO

Source text for Eikon:  ID:nGNX5br7vD 
Further company coverage:  ALRN.O 

 ((Reuters.Briefs@thomsonreuters.com;))